Under one in 10 individuals that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its inaugural advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major barriers to universal access to the injections that can aid individuals in losing considerable body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the present best projected scenario, the supply of such drugs could only cover about 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice encourages governments and firms to widen availability, through measures such as patent sharing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
The injections replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so people reduce food intake.
Individuals usually see weight reduction after several weeks of commencing the regular doses.
Studies indicates people may regain a significant portion after a year of discontinuing the medication, as their usual appetite come back.
To be overweight or obese increases your likelihood for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts people in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
